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ABSTRACT
Aims There is an increasing awareness of gender- related 
differences in patients with severe aortic stenosis and their 
outcomes after surgical aortic valve replacement (SAVR) 
and transcatheter aortic valve implantation (TAVI).
Methods Data from the IMPULSE registry were analysed. 
Patients with severe aortic stenosis (AS) were enrolled 
between March 2015 and April 2017 and stratified by 
gender. A subgroup analysis was performed to assess the 
impact of age.
Results Overall, 2171 patients were enrolled, and 48.0% 
were female. Women were characterised by a higher rate 
of renal impairment (31.7 vs 23.3%; p<0.001), were at 
higher surgical risk (EuroSCORE II: 4.5 vs 3.6%; p=0.001) 
and more often in a critical preoperative state (7.0vs 
4.2%; p=0.003). Men had an increased rate of previous 
cardiac surgery (9.4 vs 4.7%; p<0.001) and a reduced 
left ventricular ejection fraction (4.9 vs 1.3%; p<0.001). 
Concomitant mitral and tricuspid valve disease was 
substantially more common among women. Symptoms 
were highly prevalent in both women and men (83.6 vs 
77.3%; p<0.001). AVR was planned in 1379 cases. Women 
were more frequently scheduled to undergo TAVI (49.3 vs 
41.0%; p<0.001) and less frequently for SAVR (20.3 vs 
27.5%; p<0.001).
Conclusions The present data show that female patients 
with severe AS have a distinct patient profile and are 
managed in a different way to males. Gender- based 
differences in the management of patients with severe 
AS need to be taken into account more systematically to 
improve outcomes, especially for women.
INTRODUCTION
Gender differences in the presentation and 
management of patients with severe aortic 
stenosis (AS) and their outcomes after an 
intervention have received increasing atten-
tion in recent years.1 At the time of diagnosis, 
women tend to be older, more frail, more 
often symptomatic, with lower glomerular 
filtration rates and at higher surgical risk 
than their male counterparts, while men 
are frequently affected by the consequences 
of ischaemic heart disease.2–4 Furthermore, 
female hearts and their aortic annuli tend 
to be smaller which may predispose them to 
procedure- related complications and poor 
surgical outcomes.
Key questions
What is already known about this subject?
 ► There is an increasing awareness of gender- related 
differences in the characteristics of patients diag-
nosed with severe aortic stenosis (AS) and their 
outcomes after surgical aortic valve replacement 
(SAVR) and transcatheter aortic valve implantation 
(TAVI).
What does this study add?
 ► We investigated gender- related patient profiles at 
the time of diagnosis and the associated treatment 
decisions, leading to the provision of SAVR or TAVI. 
Both disease presentation and treatment approach-
es were found to differ between women and men 
with severe AS.
 ► Women were generally older and more symptomat-
ic, despite a lesser degree of concentric LV remod-
elling. TAVI was more commonly assigned to women 
than to men, with the inverse true of SAVR.
 ► These decisions appear to be appropriate in princi-
ple given the increased risk for women undergoing 
surgery.
How might this impact on clinical practice?
 ► The findings of this study may help to guide treat-
ment decisions for patients with severe AS.
 ► Future studies, such as RHEIA (NCT04160130), have 
been initiated to explore the benefits and risks of 
TAVI and SAVR in men versus women.
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These gender differences translate into a differential 
risk profile for surgical aortic valve replacement (SAVR) 
and transcatheter aortic valve implantation (TAVI). 
Indeed, recent large meta- analyses5–8 and a large retro-
spective study from the STS/ACC TVT registry9 demon-
strated improved survival in female versus male patients 
with AS undergoing TAVI despite their advanced age 
and increased rates of major peri- procedural vascular 
complications, bleeding events and strokes. In the recent 
PARTNER 3 trial,10 which compared surgery with SAVR 
in low- risk patients, subgroup analyses of the primary 
endpoint at 1 year showed no heterogeneity of treatment 
effect by gender (p=0.27), but for women the endpoint 
rate for SAVR was 18.5% (men 13.8%) and 8.1% for 
TAVI (men 8.7%), showing a clear trend for an increased 
benefit of women undergoing TAVI instead of SAVR (rate 
difference −10.4%; 95% CI −18.3% to −2.5%).
These observations have triggered an investigation 
into gender- related patient profiles at the time of diag-
nosis and into the treatment decisions made, leading to 
the provision of SAVR or TAVI. The analyses are based 
on the prospective IMPULSE database,11 which enrolled 
patients at the time of diagnosis in the echo laboratory 
and followed them for 3 months.
METHODS
The design of the prospective IMPULSE database has 
been previously described.11–15 The European registry 
spanned 23 TAVI/SAVR- equipped centres across 9 coun-
tries (Austria, Czech Republic, France, Germany, Italy, 
the Netherlands, Spain, Switzerland and the UK) and was 
set up as part of a quality of care initiative for improving 
the management of patients with severe AS. Enrolment 
took place between March 2015 and April 2017, with each 
patient providing written informed consent to partici-
pate. Neither patients nor the public were not involved 
in the design, conduct, reporting or dissemination of our 
research.
Patients
Patients aged 18 years or older who were diagnosed with 
severe AS (symptomatic or asymptomatic; defined as 
aortic valve area (AVA) <1 cm2, indexed AVA <0.6 cm2/
m2, maximum jet velocity (Vmax) >4 m/s or mean trans-
valvular gradient >40 mm Hg) after being referred for 
echocardiography at one of the participating sites were 
included in the registry. Recruitment was consecutive on 
a centre level based on the patient’s willingness to partic-
ipate. For the purposes of the present analysis, the study 
population was divided into two groups according to 
gender. A subanalysis comparing males and females aged 
over 80 years was also carried out.
Data collection
An electronic case report form was used to collect data, 
which was entered by a dedicated study nurse. Patient 
demographics, echocardiographic parameters and 
medical history were recorded at baseline, alongside 
AS- attributed symptoms (chest pain, shortness of breath 
and dizziness on exertion/syncope). Surgical risk was 
calculated using logistic EuroSCORE I and EuroSCORE 
II risk- stratification tools, with frailty determined by the 
inability to walk 5 m in ≤6 s and/or to perform activities 
of daily living.16 Stroke volume and flow rate were not 
calculated. The decision on which treatment approach 
to take (TAVI, SAVR, balloon aortic valvuloplasty (BAV), 
watchful waiting or active decision not- to- treat) and the 
time between assignment to AVR and its performance 
were then documented. All data were subject to auto-
matic checks for plausibility and completeness.
Statistics
Following descriptive analysis, continuous variables are 
presented as means with SDs, with categorical varia-
bles presented as absolute values with percentages (%). 
Comparisons between men and women were made using 
Pearson’s χ2 or Fisher’s exact test for categorical variables 
and a t- test or Mann- Whitney- Wilcoxon U test for contin-
uous variables. All statistical analysis was performed using 
SPSS V.24.0 and a p value of <0.05 was considered statis-
tically significant.
RESULTS
A total of 2171 patients were enrolled in the registry of 
which 48.0% were women (n=1130) and 52.0% men 
(n=1130) (figure 1). Patient characteristics, symptoms, 
echocardiographic variables and treatment decisions 
were compared. As for many of these variables age was a 
potential confounder, analyses were repeated for the age 
group of patients over 80 years (women n=571, mean age 
85.5 years; men n=435, mean age 85.5 years; p=0.256).
Patient characteristics
In patients diagnosed with severe AS (table 1), women were 
approximately 3 years older (79.5 vs 76.4 years; p<0.001), 
had a higher degree of renal impairment (31.7 vs 23.3%; 
p<0.001), had a higher surgical risk (EuroSCORE II: 4.5 
vs 3.6%; p=0.001) and more often in a critical preop-
erative state (7.0 vs 4.2%; p=0.003). Men, on the other 
hand, had an increased rate of previous cardiac surgery 
(9.4 vs 4.7%; p<0.001) and a reduced left ventricular ejec-
tion fraction ((LVEF) EF <30% 4.9 vs 1.3%; p<0.001). As 
many of these differences were potentially age related, we 
performed a sensitivity analysis for age. In patients older 
than 80 years, we essentially confirmed all of the observed 
differences between women and men, although the 
difference in haematological disorders and liver disease 
lost statistical significance. On the other hand, chronic 
obstructive pulmonary disease, which was borderline 
more frequent in men for the total population, became 
significantly more frequent in men versus women over 80 
years (15.2 vs 9.2%; p=0.003).
Echocardiographic parameters
Aortic valve–related parameters, such as the indexed 
AVA and the mean AV gradient were largely identical 
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between women and men (table 2). While the p value 
for the mean AV gradient was below 0.05, the means did 
not show a potentially clinically relevant difference. The 
heart of women was, on the one hand, smaller (LV mass 
128.9 g/m2 vs 135.9 g/m2; p=0.001). On the other hand, 
there was an increased relative wall thickness (0.56 vs 0.50; 
p<0.001). Concomitant mitral and tricuspid valve disease 
was substantially more common among women than 
men, with increased rates of grade III/IV mitral (12.5 vs 
9.0%; p=0.010) and tricuspid regurgitation (10.4 vs 5.5%; 
p<0.001). In a sensitivity analysis for age, the pattern of 
differences between women and men persisted, while the 
difference in the mean AV gradient as described earlier 
lost its statistical significance.
Symptom presentation
Symptoms were defined as any of chest pain, shortness of 
breath and dizziness/syncope in this registry (figure 2). 
Symptoms overall were common in both women and 
men but more frequent by approximately 6% in women 
(83.6 vs 77.3%; p<0.001). This was largely due to more 
frequent shortness of breath (77.4 vs 67.5%; p<0.001) 
and dizziness (27.4 vs 21.4%; p<0.01) in women, while 
chest pain was equally common in either gender. The 
sensitivity analysis revealed that the difference in the rate 
of dizziness/syncope was affected by age (resulting in no 
difference in patients over 80 years; 28.3 vs 28.2%), while 
other differences persisted.
Treatment decisions
Of the 2000 patients with a documented treatment deci-
sion, AVR was planned in 1379 cases (69%), with BAV, 
medical management or watchful waiting planned in the 
remaining 621 patients (31%). This split was uniform 
across genders (69.5% in women vs 68.5% in men; 
p=0.614). However, the type of AVR planned differed 
significantly, with women more frequently being sched-
uled to undergo TAVI (49.3 vs 41.0%; p<0.001) and less 
frequently for SAVR (20.3 vs 27.5%; p<0.001) (figure 3; 
table 3). A higher proportion of women also underwent 
TAVI within 3 months of the treatment decision (41.3 
vs 35.0%; p=0.004). Conversely, a higher proportion of 
men underwent SAVR within 3 months compared with 
women (19.9 vs 16.5%; p=0.047). The mean time to 
AVR (33.0±34.7 days) was comparable between gender 
groups, with the same true for TAVI (29.2±34.2) and 
SAVR (40.7±34.5 days) considered separately. The 
gender- related trends observed in the overall population 
were also seen in the subset of patients aged >80 years 
(figure 3; table 3).
DISCUSSION
In the present analysis, both disease presentation and 
treatment approach were found to differ between women 
and men with severe AS. Women were generally older and 
more symptomatic, despite a lesser degree of concentric 
LV remodelling. Although the proportion of patients 
Figure 1 Patient flow. AVR, aortic valve replacement; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve 
implantation.
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scheduled for AVR was largely comparable between 
genders, TAVI was more commonly assigned to females 
than to males, with the inverse true of SAVR. While these 
decisions appear to be appropriate in principle given the 
increased risk for women undergoing surgery, the degree 
of this location shift may be questioned in the absence 
of additional benefit of TAVI in women compared with 
men.
Gender and symptomatic presentation
Cardiac symptoms were more common in women 
compared with men. This trend is consistent with the 
observations of prior studies,3 17 and was primarily driven 
by shortness of breath and dizziness/syncope. Neverthe-
less, a lesser degree of concentric remodelling was seen in 
women at echocardiography. A similar trend was recently 
observed by Singh et al in their study into the relationship 
between LV remodelling and AS symptom onset in men 
and women,17 with other studies also reporting women to 
have a higher relative wall thickness, a smaller LV cavity 
and a lower LV mass index than men in the context of AS 
chronic pressure overload.18 19 Singh et al have suggested 
that, in the context of these diverse pathophysiolog-
ical profiles, the higher symptomatic burden in women 
may be due to higher wall stress and filling pressures.17 
Alternatively, it may be partly reflective of differences in 
physical activity levels, which are reportedly higher in men 
than in women.20 As such, women could describe or be 
perceived to have more shortness of breath due to a natu-
rally lower exercise tolerance. Indeed, dyspnoea but not 
dizziness/syncope remained significantly more common 
in women than men aged over 80 years, despite compa-
rable mean ages. Activity- dependent gender subjectivity 
may thus be a driver for the apparently higher frequency 
of symptoms in women. Finally, the higher frequency of 
concomitant tricuspid/mitral valvular disease in women 
may have impacted on symptoms, given that shortness of 
breath is also a manifestation of both of these valvular 
conditions.21 22 Regardless of the underlying explanation, 
our data support the previously reported trend towards a 
greater likelihood of symptomatic presentation in women 
compared with men with severe AS.17 Considering that 
symptomatic onset is a key consideration when deter-
mining the timing of AVR,23 this difference has important 
implications for treatment decisions.
Gender and treatment decision
Early AVR is strongly recommended in all severe sympto-
matic patients with AS, unless the intervention is unlikely 
to improve quality of life/survival or the patient has a 
Table 1 Patient characteristics
  




P valuen=1041 n=1130 n=571 n=435
Age (years) 79.5±9.5 76.4±10.2 <0.001 85.8±3.7 85.5±3.6 0.256
BMI 27.3±5.9 27.5±4.7 0.563 26.1±5.0 26.2±3.9 0.607
Comorbidities
  Haematological disorder 6.8 4.5 0.022 8.2 6.0 0.176
  Liver disease 1.5 2.9 0.024 0.9 1.4 0.543
  Extra- arterial pathology 10.0 12.3 0.093 10.6 11.3 0.712
  Renal impairment* 31.7 23.3 <0.001 42.9 34.2 0.009
  Diabetes requiring insulin 8.2 8.8 0.633 5.6 6.2 0.696
  COPD 10.3 12.4 0.128 9.2 15.2 0.003
  Pulmonary hypertension† 8.6 8.4 0.854 10.6 10.6 1.000
  Endocarditis 0.5 0.5 0.872 0.4 0.5 1.000
Cardiac history
  Recent MI 3.1 2.9 0.824 3.9 3.5 0.729
  LVEF <30% 1.3 4.9 <0.001 1.3 7.3 <0.001
  Previous cardiac surgery 4.7 9.4 <0.001 4.0 9.7 <0.001
Critical preoperative status 7.0 4.2 0.003 8.5 3.9 0.004
Frailty (severe) 6.0 4.3 0.067 8.5 7.5 0.583
Logistic EuroSCORE I (%) 16.5±13.5 14.7±14.2 0.056 21.9±14.4 20.4±15.5 0.305
EuroSCORE II (%) 4.5±5.3 3.6±4.7 0.001 5.6±6.0 4.7±5.1 0.023
Values are reported as mean with SDs or as percentage.
*Defined as creatinine clearance <50 mL/min or dialysis.
†Defined as pulmonary systolic pressure >55 mm Hg.
BMI, body mass index; COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction; MI, myocardial infarction.
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life expectancy of less than 1 year.23 Therefore, given that 
symptomatic presentation was more common in women, 
it is surprising that the proportion of patients assigned 
to AVR did not differ according to gender. This may be 
partly explained by the counterbalancing effect of a more 
severely reduced LVEF in men, which is an independent 
indication for AVR in asymptomatic patients.23 Regard-
less, nearly two- thirds of the present study population 
were denied a life- saving AVR intervention. This rate is 
similar to that reported by the Euro Heart Survey prior 
to the widespread diffusion of TAVI.24 Consequently, it 
would appear that this minimally invasive alternative to 
SAVR is being used as an approach to risk reduction in 
patients previously considered for surgery, but not as a 
novel option in those considered inoperable. As such, 
there may be considerable scope for increasing the rate 
of AVR in clinical practice.
The type of AVR planned differed significantly between 
genders. In line with previous studies, women were less 
frequently assigned to SAVR25 26; however, contrary to the 
existing literature suggesting that comparable propor-
tions of men and women undergo TAVI,9 27 a higher rate 
of TAVI was observed in the latter. This reciprocal trend 
may be partly explained by the slightly higher surgical risk 
scores, the older age of our female patients and a smaller 
valvular anatomy/aortic annulus which are favouring 
patient prosthesis mismatch in women.28–30 The factors 
are also favouring TAVI over SAVR according to European 
guidelines.23 More specifically, the higher prevalence of 
renal impairment in women (apparent both overall and 
in the elderly subgroup) is likely to have been a strong 
deterrent for cardiac surgery, given that it has been 
previously associated with increased in- hospital mortality 
and length of hospital/ICU stay in individuals under-
going SAVR.31 This association has not been observed 
in patients undergoing TAVI,31 strengthening the argu-
ment for this minimally invasive alternative in individuals 
with kidney disease. A further consideration is the higher 
prevalence of coronary artery disease generally seen in 
men compared with women,26 32 which may have resulted 
in a tendency towards the performance of more AVR/
coronary artery bypass graft hybrid interventions in men, 
increasing the overall proportion undergoing SAVR. 
Unfortunately, data to support this speculation were not 
available in the present analysis. Finally, assuming that 
the physicians responsible for treatment decisions were 
familiar with contemporary real- world AVR studies, they 
may have been aware of data suggesting women to have 
Table 2 Echocardiographic parameters
  




P valuen=1041 n=1130 n=571 n=435
AV parameters
  Indexed AVA (cm2/m2) 0.39±0.11 0.40±0.11 0.274 0.40±0.11 0.39±0.11 0.471
  Mean AV gradient (mm Hg) 47.8±15.2 46.5±14.2 0.031 47.1±14.7 45.7±14.7 0.148
  Aortic regurgitation grade III/IV 7.6 8.5 0.467 6.2 8.1 0.252
  LVEF (%) 57.9±11.0 54.0±12.8 <0.001 57.4±11.1 52.6±13.5 <0.001
Left ventricle parameters
  LV hypertrophy* 62.5 61.8 0.748 64.0 64.6 0.849
  LV- ESD (mm) 29.0±9.0 33.3±10.5 <0.001 29.0±9.0 33.3±10.5 <0.001
  LV- EDD (mm) 44.4±8.4 49.1±8.3 <0.001 44.4±8.4 49.1±8.3 <0.001
  IVS (mm) 13.9±2.7 14.0±2.6 0.895 13.9±2.7 14.0±2.6 0.895
  PW (mm) 12.2±2.3 12.3±2.4 0.837 12.2±2.3 12.3±2.4 0.837
  RWT† (cm) 0.56±0.16 0.50±0.13 <0.001 0.58±0.16 0.52±0.14 <0.001
  LV mass (g) 219.1±72.3 261.6±75.7 <0.001 219.2±68.5 256.9±78.9 <0.001
  Indexed LV mass (g/m2) 128.9±42.0 135.9±39.5 0.001 133.5±41.2 140.0±43.7 0.055
Other valve parameters
  Mitral regurgitation III/IV 12.5 9.0 0.010 17.9 13.1 0.041
  Mitral stenosis III/IV 2.2 1.5 0.267 2.2 1.5 0.431
  Tricuspid regurgitation III/IV 10.4 5.5 <0.001 13.0 8.6 0.032
Values are reported as mean with SD or as percentage.
*Defined as LV wall thickness >12 mm.
†Calculated as 2×PW/LV−EDD.
AV, aortic valve; AVA, aortic valve area; LVEF, left ventricular ejection fraction; LV, left ventricular; ESD, end- systolic dimension; EDD, end- 
diastolic dimension; IVS, interventricular septal thickness at end- diastole; PW, posterior wall thickness at end diastole; RWT, relative wall 
thickness.
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superior long- term outcomes and achieve a greater clin-
ical benefit after TAVI compared with SAVR,33 34 with 
greater survival compared with men undergoing this 
minimally invasive procedure.5 9 This may also have 
contributed to the gender- related disparity in preferred 
AVR type.
Interestingly, several of the factors highlighted in 
contemporary guidelines as instrumental for choosing 
between TAVI and SAVR were significantly different 
between gender groups, but appeared to have little 
influence on clinical decision- making. For example, 
significantly more men than women had previously 
undergone cardiac surgery, which is a characteristic in 
favour of TAVI,23 yet fewer men underwent this interven-
tion. Furthermore, age >75 years is another guideline- 
recommended factor favouring TAVI.23 Although there 
was a nominally higher rate of TAVI and lower rate of 
SAVR in elderly compared with all patients, the sex- 
dependent differences in treatment decision persisted, 
with relatively fewer men undergoing TAVI, despite 
comparable mean ages. Thus, the observed differences 
in TAVI/SAVR assignment cannot be explained purely as 
a function of age.
Gender and time to intervention
The waiting time between referral for AVR and its perfor-
mance appeared to be unrelated to gender, averaging 
at approximately 30 days in both males and females. 
This is longer than the 20.3 days reported by a 2014 
study,35 perhaps reflecting the temporal trend towards an 
increasing prevalence of severe AS in the ageing popula-
tion, which in turn places a higher burden on healthcare 
providers.36
TAVI waiting times were shorter than SAVR waiting times 
in both males and females, with no significant differences 
between gender groups. This suggests that the urgency 
of the intervention is not sex dependent and largely is 
restricted by procedure availability. The differences in 
Figure 2 Cardiac symptoms at baseline in (A) all patients 
and (B) those aged >80 years. **p<0.01, ***p<0.001. NYHA 
class III or IV: female 441/1024 (43.1) vs male 418/1118 
(37.4); p=0.007. Angina class III or IV: female 43/909 (4.7) vs 
male 48/992 (4.8); p=0.912.
Figure 3 Treatment decision in (A) all patients and (B) those 
aged >80 years. AVR, aortic valve replacement; M, months; 
SAVR, surgical aortic valve implantation; TAVI, transcatheter 
aortic valve implantation. *p< 0.05, ***p<0.001. †Balloon 
aortic valvuloplasty, medical management or watchful waiting 
planned. Values are proportional to the number of patients 
with known treatment decisions.
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the proportions of male and female patients who under-
went TAVI and SAVR within 3 months of the treatment 
decision are likely to reflect general differences in AVR 
assignment. Indeed, when expressed as a proportion of 
patients initially assigned to the procedure, the rate of 
TAVI performance within 3 months was the same in men 
and women. A slight sex- dependent disparity may exist 
in terms of SAVR, with only 72% of the assigned males 
undergoing the procedure within 3 months compared 
with 81% of the assigned females (p=0.026). Specula-
tively, this may be related to the lower rate of symptoms 
in males, making them lower priority for such an invasive 
procedure. This merits further investigation.
Limitations
The principal limitation in the present analysis is the lack 
of adjustment for confounding variables when comparing 
genders. This means that it is difficult to determine sex- 
specific trends from those influenced by the particular 
characteristics of male and female patients with AS. On 
the other hand, adjustment for gender- specific variables 
would abolish the clear difference between both gender, 
making conclusions of the gender impact impossible. As 
the two are closely linked, the present data provide an 
overview of the multifactorial gender- related influences 
that are relevant to clinical practice. While the wide 
range of countries included is a strength of the registry, 
our findings may not be generalisable to regions outside 
of Europe. The interventional portion of the quality of 
care initiative did not take place until month 3, so did not 
influence the data presented.
Clinical implications and perspectives
There is an ever growing number of patients for whom 
TAVI is preferred over SAVR, which is due to growing 
body of evidence for a benefit of TAVI over SAVR in 
high and prohibitive surgical risk, and also interme-
diate and even risk patients. This trend is even more 
important in women than in men, as the benefits of 
TAVI are pronounced in women: A meta- analysis of 
randomised trials compared TAVI with SAVR and 
found that TAVI was associated with a survival benefit 
compared with SAVR in women but not men.37 38 A 
further meta- analysis found TAVI to be associated with 
reduced mortality compared with SAVR in women at 
both 1 (OR 0.68, 95% CI 0.50 to 0.94) and 2 years of 
follow- up (OR 0.74, 95% CI 0.58 to 0.95), whereas 
there was no difference among men at either time 
point.38 The difference in treatment effect between 
the sexes was significant at both 1 (p=0.02) and 2 years 
(p=0.04). In the recent PARTNER 3 trial,10 which is 
pivotal in showing the benefits of TAVI over SAVR in 
low- risk patients, subgroup analyses of the primary 
endpoint at 1 year showed no heterogeneity of treat-
ment effect by gender (p=0.27). However, apart from 
this non- significant p value, the endpoint rate in 
SAVR- treated women was 18.5% (vs 13.8% in men) 
and 8.1% for TAVI (vs 8.7% in men), showing a clear 
trend for an increased benefit of women undergoing 
TAVI instead of SAVR (rate difference −10.4%; 95% CI 
−18.3% to −2.5%). To shed further light on the poten-
tial benefits of TAVI in women, there is an ongoing 
clinical trial ( ClinicalTrials. gov: NCT04160130), 
which compares either strategy in women undergoing 
TAVI. Women with severe symptomatic aortic stenosis, 
with any but prohibitive surgical risk status, will be 
randomised 1:1 to undergo aortic valve intervention 
with either transfemoral TAVR with the SAPIEN 3 or 
SAPIEN 3 Ultra device or SAVR and followed up for 
1 year. The authors pursue non- inferiority, but the trial 
is also powered to show superiority of this approach in 
women.39
Table 3 Treatment decision and time to intervention
  




P valuen=954 n=1046 n=509 n=390
Decision to perform AVR 69.5 68.5 0.614 67.2 64.9 0.466
  AVR performed in 3 months 57.8 54.9 0.195 55.4 54.4 0.755
  Time to intervention (days) 33.3±34.1 32.8±35.2 0.825 30.5±33.8 27.8±34.0 0.374
Decision made for TAVI 49.3 41.0 <0.001 60.7 53.9 0.039
  TAVI performed in 3 months 41.3 35.0 0.004 50.3 45.4 0.144
  Time to intervention (days) 30.2±34.2 28.1±34.1 0.389 29.4±33.5 26.6±35.0 0.382
Decision made for SAVR 20.3 27.5 <0.001 6.5 11.1 0.015
  SAVR performed in 3 months 16.5 19.9 0.047 5.1 9.0 0.022
  Time to intervention (days) 40.8±32.8 40.7±35.8 0.991 40.9±35.4 34.1±27.7 0.387
Decision not to perform AVR* 30.5 31.5 0.614 32.8 35.1 0.466
Values are reported as mean with SD or as percentage.
*Balloon aortic valvuloplasty, medical management or watchful waiting planned instead.
AVR, aortic valve replacement; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve replacement.
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CONCLUSION
The present contemporary data from major treatment 
centres across Europe show that female patients with 
severe AS have a distinct patient profile and are managed 
in a different way to males with the same condition. 
Gender- based differences in the management of patients 
with severe AS need to be taken into account more system-
atically to improve outcomes, especially for women.
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